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Cancer stem cells (CSCs)/cancer-initiating cells (CICs) are characterized as a small population of cancer cells that have
high tumor-initiating ability. CSCs/CICs are resistant to several cancer therapies, and eradication of CSCs/CICs is essential
to cure cancer. How can we eradicate CSCs/CICs? Cytotoxic T lymphocytes (CTLs) might be a promising answer.
Cancer stem-like cells (CSCs)/cancer-
initiating cells (CICs) are defined as a
small population of cancer cells that have
(1) high tumor-initiating ability, (2) self-
renewal ability and (3) differentiation
ability (Fig.1A).
1 In recent studies,
CSCs/CICs have shown to be resistant
to cancer therapies by their senescence
state, high expression of transporters to
efflux anti-cancer drugs, high expression
of apoptosis inhibitors, low expression of
reactive oxygen species.
2 Thus, the action
of CSCs/CICs are regarded as major
mechanisms of cancer recurrence, distant
metastasis and treatment resistance. How-
ever, effective cancer treatment targeting
CSCs/CICs effectively have not been
reported so far.
The prominent nature of the acquired
immune system is its antigen specificity
due to antigen-specific receptors including
T cell receptors and B cell receptors, and
isolation of human tumor-associated anti-
gens (TAAs) has enabled us to target caner
cells specifically in an antigen-specific
manner.
3 Cancer immunotherapy trials
using TAAs have recently been performed
in several facilities and significant results
have been obtained.
4 However, it is still
not clear whether the immune system can
recognize therapy-resistant CSCs/CICs
or not. Some reports on immunity and
CSCs/CICs have recently been published,
and natural killer (NK) cells and cdT
cells have been shown to recognize CSCs/
CICs derived from human colon cancer
and gliomas; however CTLs, which are
a major component of the acquired
immune system, have not been charac-
terized yet.
5
We analyzed the relation between CTLs
and CSCs/CICs.
6 We isolated CSCs/CICs
from human colon cancer cells using a side
population (SP) technique. Since CTLs
recognize antigenic peptides derived from
TAAs, we evaluated the expression of
TAAs in colon CSCs/CICs and non-
CSCs/CICs. Colon CSCs/CICs expressed
CEP55, one of the TAAs, at the same
level as did non-CSCs/CICs. In a further
study, we evaluated the expression of
several TAAs in both CSCs/CICs and
non-CSCs/CICs, and we found that the
expression pattern can be classified into
the following groups (Fig.1B, unpub-
lished data): (1) CSC/CIC antigens,
which are expressed in CSCs/CICs but
not in non-CSCs/CICs (e.g., MAGE-A3
and MAGE-A4); (2) shared antigens,
which are expressed in both CSCs/CICs
and non-CSCs/CICs (e.g., CEP55,
SURVIVIN); and (3) non-CSC/CIC
antigens, which are expressed in only
non-CSCs/CICs but not in CSCs/CICs
(e.g., AMACR, HIFPH3). Therefore,
CEP55 is one of the (2) shared antigens.
Since we have established CTL clone
#41 which is specific for CEP55-derived
antigenic peptide,
7,8 we evaluated the
reactivity of CTL clone #41 for colon
CSCs/CICs and non-CSCs/CICs. Inter-
estingly, CTL clone #41 recognized both
colon CSCs/CICs and non-CSCs/CICs at
the same level in vitro. Furthermore, CTL
clone #41 inhibited the tumor-initiating
ability of colon CSCs/CICs in vivo. These
findings clearly indicate that treatment-
resistant colon CSCs/CICs, as well as
non-CSCs/CICs are sensitive to CTLs.
Therefore, CTL-based immunotherapy
is a promising approach to target
CSCs/CICs.
In the next stage, another question has
emerged. Which are the best TAAs for
CSC/CIC-targeting cancer immunother-
apy: (1) CSC/CIC antigens, (2) shared
antigens or (3) non-CSC/CIC antigens?
Non-CSC/CIC antigens do not seem to
be suitable for targeting CSCs/CICs since
they are not expressed in CSCs/CICs.
Further analyses are under way to address
thes questions, and we have found that
targeting CSC/CIC antigens was more
effective than targeting shared antigens in
a CTL adoptive transfer model and a
DNA vaccination model (unpublished
data). Both CSC/CIC antigens and shared
antigens are expressed in CSCs/CICs;
however, the anti-tumor effects are
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different. We are not sure about the exact
mechanisms and we are now analyzing;
however, these data indicate that targeting
CSC/CIC specific antigens is more effect-
ive than targeting shared antigens.
The numbers of CTL clones are very
restricted and limited in vivo, and the
maximum numbers of one CTL clone
might be about 10
7 to 10
8 cells in the
whole body. On the other hand, cancer
tissues contain 5  10
8 cancer cells per
gram,
9 and advanced cancer tissues may
therefore contain more than 10
10 cancer
cells. It is easy to imagine the difficulty in
eliminating all cancer cells with such a
limited number of CTLs (Estimated
effector/target ratio is about 0.001 in the
case of 10
7 CTL and 10
10 cancer cells.).
On the other hand, if we focus on just
CSCs/CICs targeting CSC/CIC antigens,
the situation will be improved (Estimated
Figure1. CSC/CIC targeting immunotherapy. (A) Characters of CSC/CIC. CSC/CIC has three distinct characteristics: (1) high tumor-initiating ability,
(2) self-renewal ability and (3) differentiation ability. (B) Three groups of tumor-associated antigens. Tumor-associated antigens can be classified into 3
groups according to the expression in CSC/CIC and non-CSC/CIC: (1) CSC/CIC antigens, which are expressed in CSCs/CICs but not in non-CSCs/CICs (e.g.,
MAGE-A3 and MAGE-A4); (2) shared antigens, which are expressed in both CSCs/CICs and non-CSCs/CICs (e.g., CEP55, SURVIVIN); and (3) non-CSC/CIC
antigens, which are expressed in only non-CSCs/CICs but not in CSCs/CICs (e.g., AMACR, HIFPH3). (C) CSC/CIC-targeting immunotherapy. CSC/CIC antigen
specific CTLs recognize only higher tumorigenic CSCs/CICs, whereas shared antigen specific CTLs, NK cells and cdT cells recognize both CSCs/CICs and
non-CSCs/CICs. CSCs/CICs might be eliminated most efficiently by CSC/CIC antigen-specific CTLs.
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effector/target ratio is about 0.1 in the case
of 10
7 CTL, 10
10 cancer cells and 1%
frequency of CSCs/CICs.). Therefore,
targeting CSC/CIC antigens might be a
more effective approach to eradicate higher
tumorigenic CSCs/CICs and may bring
about greater anti-tumor effects (Fig.1C).
As stated above, NK cells and cdT cells
have been reported to recognize CSSs/
CICs. However, these immune cells
belong to the innate immune system and
do not recognize target cells in an antigen-
specific manner. Thus, activation of these
cells in vivo may not be more effective
than CSC/CIC antigen-specific CTLs
(Fig.1C). CTL adoptive transfer therapy
has recently been described in detail,
10 and
huge numbers of CTLs can be obtained
by in vitro culture. Therefore, (2) shared
antigens may also be suitable candidates
for CTL adoptive transfer therapy using
high numbers of CTLs.
In summary, CTLs can recognize
CSCs/CICs as well as non-CSCs/CICs,
and targeting CSC/CIC antigens with
CTLs may be a reasonable approach for
CSC/CIC targeting therapy.
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